Clinical Trial

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

Study acronym: CHIPPI
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-02-14; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2026-03-12
Status change: Not Yet Recruiting → Recruiting 2019-05-13
Trial Details
NCT Number NCT03842982
Lead Sponsor Centre Oscar Lambret
Conditions Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma
Enrollment 362 participants
Start Date 2019-05-03
Primary Completion 2031-02-01 (estimated)
Study Completion 2031-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-16